Sonoma Pharmaceuticals Gross Profit Growth & History (SNOA)
Sonoma Pharmaceuticals's gross profit was $7.4M for fiscal 2026.
View full Sonoma Pharmaceuticals company overviewSonoma Pharmaceuticals annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $7.4M | $1.9M | +35.68% |
| 2025 | 2025-03-31 | $5.5M | $720,000 | +15.17% |
| 2024 | 2024-03-31 | $4.7M | $268,000 | +5.99% |
| 2023 | 2023-03-31 | $4.5M | $484,000 | +12.12% |
| 2022 | 2022-03-31 | $4.0M | −$2.6M | −39.12% |
| 2021 | 2021-03-31 | $6.6M | −$1.6M | −19.24% |
| 2020 | 2020-03-31 | $8.1M | −$758,000 | −8.54% |
| 2019 | 2019-03-31 | $8.9M | $1.6M | +21.48% |
| 2018 | 2018-03-31 | $7.3M | $1.6M | +28.97% |
| 2017 | 2017-03-31 | $5.7M | $3.0M | +114.05% |
| 2016 | 2016-03-31 | $2.6M | −$4.6M | −63.67% |
| 2015 | 2015-03-31 | $7.3M | −$1.1M | −13.21% |
| 2014 | 2014-03-31 | $8.4M | −$2.3M | −21.84% |
| 2013 | 2013-03-31 | $10.7M | $2.0M | +23.28% |
| 2012 | 2012-03-31 | $8.7M | $2.6M | +41.90% |
| 2011 | 2011-03-31 | $6.1M | — | — |
Sonoma Pharmaceuticals quarterly gross profit
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $2.6M | $1.1M | +76.02% |
| Q4 2026 | 2026-03-31 | $2.2M | $653,000 | +42.74% |
| Q3 2026 | 2025-12-31 | $1.6M | $380,000 | +29.92% |
| Q2 2026 | 2025-09-30 | $2.1M | $759,000 | +55.77% |
| Q1 2026 | 2025-06-30 | $1.5M | $158,000 | +12.10% |
| Q4 2025 | 2025-03-31 | $1.5M | $437,000 | +40.05% |
| Q3 2025 | 2024-12-31 | $1.3M | −$190,000 | −13.01% |
| Q2 2025 | 2024-09-30 | $1.4M | $371,000 | +37.47% |
| Q1 2025 | 2024-06-30 | $1.3M | $102,000 | +8.47% |
| Q4 2024 | 2024-03-31 | $1.1M | $627,000 | +135.13% |
| Q3 2024 | 2023-12-31 | $1.5M | $629,000 | +75.69% |
| Q2 2024 | 2023-09-30 | $990,000 | −$546,000 | −35.55% |
| Q1 2024 | 2023-06-30 | $1.2M | −$442,000 | −26.85% |
| Q4 2023 | 2023-03-31 | $464,000 | $368,000 | +383.33% |
| Q3 2023 | 2022-12-31 | $831,000 | −$372,000 | −30.92% |
| Q2 2023 | 2022-09-30 | $1.5M | $295,000 | +23.77% |
| Q1 2023 | 2022-06-30 | $1.6M | $193,000 | +13.28% |
| Q4 2022 | 2022-03-31 | $96,000 | $289,000 | — |
| Q3 2022 | 2021-12-31 | $1.2M | −$792,000 | −39.70% |
| Q2 2022 | 2021-09-30 | $1.2M | −$1.3M | −50.40% |
| Q1 2022 | 2021-06-30 | $1.5M | −$802,000 | −35.57% |
| Q4 2021 | 2021-03-31 | −$193,000 | −$1.8M | — |
| Q3 2021 | 2020-12-31 | $2.0M | −$6,000 | −0.30% |
| Q2 2021 | 2020-09-30 | $2.5M | $327,000 | +15.03% |
| Q1 2021 | 2020-06-30 | $2.3M | −$38,000 | −1.66% |
| Q4 2020 | 2020-03-31 | $1.7M | −$222,000 | −11.84% |
| Q3 2020 | 2019-12-31 | $2.0M | −$846,000 | −29.72% |
| Q2 2020 | 2019-09-30 | $2.2M | −$252,000 | −10.38% |
| Q1 2020 | 2019-06-30 | $2.3M | $562,000 | +32.47% |
| Q4 2019 | 2019-03-31 | $1.9M | $543,000 | +40.77% |
| Q3 2019 | 2018-12-31 | $2.8M | $479,000 | +20.23% |
| Q2 2019 | 2018-09-30 | $2.4M | $579,000 | +31.33% |
| Q1 2019 | 2018-06-30 | $1.7M | −$31,000 | −1.76% |
| Q4 2018 | 2018-03-31 | $1.3M | −$613,000 | −31.52% |
| Q3 2018 | 2017-12-31 | $2.4M | $662,000 | +38.80% |
| Q2 2018 | 2017-09-30 | $1.8M | $812,000 | +78.38% |
| Q1 2018 | 2017-06-30 | $1.8M | $781,000 | +79.61% |
| Q4 2017 | 2017-03-31 | $1.9M | $3.7M | — |
| Q3 2017 | 2016-12-31 | $1.7M | $1.3M | +274.95% |
| Q2 2017 | 2016-09-30 | $1.0M | −$1.1M | −50.43% |
| Q1 2017 | 2016-06-30 | $981,000 | −$892,000 | −47.62% |
| Q4 2016 | 2016-03-31 | −$1.8M | −$3.8M | — |
| Q3 2016 | 2015-12-31 | $455,000 | −$1.2M | −72.52% |
| Q2 2016 | 2015-09-30 | $2.1M | $358,000 | +20.67% |
| Q1 2016 | 2015-06-30 | $1.9M | −$33,000 | −1.73% |
| Q4 2015 | 2015-03-31 | $2.0M | $611,000 | +44.18% |
| Q3 2015 | 2014-12-31 | $1.7M | −$453,000 | −21.48% |
| Q2 2015 | 2014-09-30 | $1.7M | −$973,000 | −35.97% |
| Q1 2015 | 2014-06-30 | $1.9M | −$294,000 | −13.36% |
| Q4 2014 | 2014-03-31 | $1.4M | −$805,000 | −36.79% |
| Q3 2014 | 2013-12-31 | $2.1M | −$362,000 | −14.65% |
| Q2 2014 | 2013-09-30 | $2.7M | −$495,000 | −15.47% |
| Q1 2014 | 2013-06-30 | $2.2M | −$684,000 | −23.72% |
| Q4 2013 | 2013-03-31 | $2.2M | $53,000 | +2.48% |
| Q3 2013 | 2012-12-31 | $2.5M | $619,000 | +33.42% |
| Q2 2013 | 2012-09-30 | $3.2M | $422,000 | +15.19% |
| Q1 2013 | 2012-06-30 | $2.9M | $935,000 | +47.97% |
| Q4 2012 | 2012-03-31 | $2.1M | $205,000 | +10.62% |
| Q3 2012 | 2011-12-31 | $1.9M | $703,000 | +61.18% |
| Q2 2012 | 2011-09-30 | $2.8M | $1.1M | +66.05% |
| Q1 2012 | 2011-06-30 | $1.9M | $560,000 | +40.32% |
| Q4 2011 | 2011-03-31 | $1.9M | — | — |
| Q3 2011 | 2010-12-31 | $1.1M | — | — |
| Q2 2011 | 2010-09-30 | $1.7M | — | — |
| Q1 2011 | 2010-06-30 | $1.4M | — | — |
Sonoma Pharmaceuticals gross profit trends
Over the last five fiscal years, Sonoma Pharmaceuticals's gross profit increased from $6.6M to $7.4M, a change of $856,000. The latest reported quarter, Q1 2027, shows $2.6M.
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sonoma Pharmaceuticals source filings ↗